IndraLab
Statements
reach
"Most oncogenic activities that lead to constitutive activation of ERK1/2 signalling occur upstream of ERK1/2 activation, including overexpression of receptor tyrosine kinases such as epidermal growth factor receptor (EGFR), activating mutations in receptor tyrosine kinases, sustained autocrine or paracrine production of activating ligands, as well as Ras mutations and B-Raf mutations, resulting in enhanced or constitutive downstream activation of the Raf-MEK-ERK pathway."
reach
"In a majority of human cancers, the PI3K and AKT pathway is frequently activated by the activating mutations of PI3K p110alpha (PIK3CA) and the loss or inactivating mutation of PTEN, whereas hyper activation of MEK and ERK signaling driven by mutant RAS and BRAF is also a common oncogenic event in a variety of cancers [XREF_BIBR, XREF_BIBR]."
reach
"However, none of the TKI resistant cell lines showed mutations of the most affected regions of the genes (amino acids 12, 13 and 60 in K-RAS, amino acids 12, 13, and 61 in N-RAS; data not shown), a finding which was scarcely unexpected because RAS mutations would not only stimulate PI3K, but also ERK1/2 in an imatinib-insensitive manner."
reach
"The dysregulation of these pathways is very common in many cancer types : Receptor Tyrosine Kinases (RTKs) amplification and mutations, PIK3CA or Ras mutations, and loss-of-function mutations in negative regulators such as PTEN, collaborate to constitutively activate either PI3K and Akt or Ras and ERK signaling coupled to mTOR signaling."
reach
"Whereas a RAS mutation in other carcinomas might activate both ERK and PI3K signaling, we propose that prostate tumors have an alternative way to activate these pathways : PTEN deletion (PI3K and AKT activation) coupled with oncogenic ETS-overexpression (activation of RAS and ERK target genes)."
reach
"Oncogenic RAS mutations, which activate both the RAF-MAPK/ERK (mitogen-activated protein kinase) and phosphoinositide 3-kinase (PI3K)-AKT signalling pathways, are among the most prevalent genetic changes found in human cancers, occurring in approximately 20% of human tumors [13,14]."
reach
"The CAM dependent step in the Erk1/2 activation cascade is downstream of Ras activation, because inhibitors of CAM antagonize Erk1/2 activation induced by constitutively activated mutants of Ras and c-Src but not by constitutively activated mutants of Raf and MEK (mitogen and extracellular signal regulated kinase)."
reach
"These results suggest that the wild-type p53 has a weak effect on RAS expression and that the RAS mutants V12, S35 and E38 activate the ERK cascade and weaken p53 activity to promote proliferation and apoptosis resistance, while C40 activates the AKT cascade and has little effect on p53 expression and thus inhibits anti-apoptotic processes and proliferation."